{"id":"W4388524266","doi":"10.1183/13993003.02029-2022","title":"Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one<i>F508del</i>allele: 144-week interim results from a 192-week open-label extension study","year":2023,"lang":"en","type":"article","venue":"European Respiratory Journal","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"ca_institutions":"St. Paul's Hospital; St. Michael's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Genentech; Grifols; Vertex Pharmaceuticals; Ionis Pharmaceuticals; Deutsches Zentrum für Infektionsforschung; Basilea Pharmaceutica; Insmed; Gilead Sciences; Shionogi; Arrowhead Pharmaceuticals; European Federation of Pharmaceutical Industries and Associations; Sanofi; Deutsches Zentrum für Lungenforschung; AstraZeneca; American Thoracic Society","keywords":"Ivacaftor; Discontinuation; Medicine; Tolerability; Interim; Adverse effect; Confidence interval; Interim analysis; Internal medicine; Cystic fibrosis; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004491642,0.0006827684,0.001345516,0.0002975891,0.0004310265,0.0007194932,0.0004930003,0.00129716,0.002195801],"category_scores_gemma":[0.002247681,0.0003011493,0.00178456,0.0002035156,0.0004924581,0.0008392236,0.0003399155,0.001894515,0.0005679054],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004037495,"about_ca_system_score_gemma":0.0006159469,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004226142,"about_ca_topic_score_gemma":0.0007655867,"domain_scores_codex":[0.9988881,0.000550829,0.00008610985,0.000142628,0.000179929,0.0001524532],"domain_scores_gemma":[0.9976222,0.0004950066,0.0008661404,0.000182728,0.0002723566,0.0005615953],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.790525,0.03004193,0.03876651,0.0006969731,0.001703457,0.0002763968,0.0004165691,0.0007408641,0.03289875,0.00009799398,0.0017635,0.1020721],"study_design_scores_gemma":[0.2764611,0.5731857,0.1367439,0.0001411541,0.0022741,0.000518183,0.0001493614,0.000770839,0.006678695,0.0002083894,0.00279742,0.00007109517],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996713,0.001472069,0.0001928202,0.000112938,0.00003098838,0.0003914044,0.000528504,0.00002195476,0.0005361807],"genre_scores_gemma":[0.9968988,0.0005324432,0.0004675309,0.0002453583,0.00008532367,0.000463564,0.0007190286,0.000007915649,0.0005800933],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004491642,"threshold_uncertainty_score":0.02375436,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06974632485574715,"score_gpt":0.3339663486792207,"score_spread":0.2642200238234735,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}